FY2024 Earnings Forecast for VIGL Issued By William Blair

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Equities research analysts at William Blair issued their FY2024 earnings per share (EPS) estimates for Vigil Neuroscience in a note issued to investors on Tuesday, December 3rd. William Blair analyst S. Schram anticipates that the company will post earnings per share of ($2.00) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.09) per share. William Blair also issued estimates for Vigil Neuroscience’s FY2025 earnings at ($2.30) EPS.

Several other brokerages have also issued reports on VIGL. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a research note on Friday, November 8th. Guggenheim reduced their target price on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Wedbush boosted their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat.com, Vigil Neuroscience currently has an average rating of “Moderate Buy” and an average target price of $16.60.

Vigil Neuroscience Stock Up 0.9 %

Shares of VIGL stock opened at $2.33 on Friday. The firm has a 50 day moving average of $3.31 and a 200-day moving average of $3.59. The company has a market cap of $95.25 million, a price-to-earnings ratio of -1.13 and a beta of 1.65. Vigil Neuroscience has a 52 week low of $2.08 and a 52 week high of $6.06.

Hedge Funds Weigh In On Vigil Neuroscience

A number of hedge funds have recently added to or reduced their stakes in VIGL. Ensign Peak Advisors Inc raised its position in Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock valued at $1,580,000 after buying an additional 166,442 shares during the last quarter. abrdn plc purchased a new position in Vigil Neuroscience during the third quarter worth about $799,000. Point72 Asset Management L.P. purchased a new position in Vigil Neuroscience during the second quarter worth about $5,940,000. Vanguard Group Inc. grew its position in Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after purchasing an additional 95,276 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vigil Neuroscience in the 2nd quarter valued at about $87,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.